Pyruvate attenuates the anti-neoplastic effect of carnosine independently from oxidative phosphorylation

@article{Oppermann2016PyruvateAT,
  title={Pyruvate attenuates the anti-neoplastic effect of carnosine independently from oxidative phosphorylation},
  author={Henry Oppermann and Lutz Schnabel and J{\"u}rgen Meixensberger and Frank Gaunitz},
  journal={Oncotarget},
  year={2016},
  volume={7},
  pages={85848 - 85860}
}
Here we analyzed whether the anti-neoplastic effect of carnosine, which inhibits glycolytic ATP production, can be antagonized by ATP production via oxidative phosphorylation fueled by pyruvate. Therefore, glioblastoma cells were cultivated in medium supplemented with glucose, galactose or pyruvate and in the presence or absence of carnosine. CPI-613 was employed to inhibit the entry of pyruvate into the tricarboxylic acid cycle and 2,4-dinitrophenol to inhibit oxidative phosphorylation. Energy… 

Figures and Tables from this paper

Krebs cycle: activators, inhibitors and their roles in the modulation of carcinogenesis

To determine the particularities in the energy metabolism of cancer cells, focusing on the main nutritional substrates, such as glucose and glutamine, evaluating lactate dehydrogenase as a potential marker of malignancy and estimating activators and inhibitors in cancer treatment is determined.

Carnosine inhibits glioblastoma growth independent from PI3K/Akt/mTOR signaling

Carnosine’s anti-neoplastic effect is independent from PI3K/Akt/mTOR signaling and should be considered for therapy, especially as it is a naturally occurring compound that has already been used for the treatment of other diseases without indication of side-effects.

L-Carnosine Stimulation of Coenzyme Q10 Biosynthesis Promotes Improved Mitochondrial Function and Decreases Hepatic Steatosis in Diabetic Conditions

This work suggests that carnosine exerts beneficial effects on hepatic CoQ synthesis and when combined with CoQ, improves mitochondrial function and cellular redox balance in the liver of diabetic mice.

Erythrocytes Prevent Degradation of Carnosine by Human Serum Carnosinase

It is demonstrated for the first time that erythrocytes can take up carnosine, and, most importantly, thereby prevent its degradation by human serum carnosinase.

Targeting Altered Energy Metabolism in Colorectal Cancer: Oncogenic Reprogramming, the Central Role of the TCA Cycle and Therapeutic Opportunities

The identified cancer-specific metabolic transformations provided new therapeutic targets for the development of small molecule inhibitors, including α-lipoic acid derivative CPI-613, an inhibitor of both PDC and KGDH, and delineate its anti-tumor effects for targeted therapy.

Carnosine, Small but Mighty—Prospect of Use as Functional Ingredient for Functional Food Formulation

The present review aimed to provide recent knowledge on carnosine properties and distribution, its metabolism (synthesis and degradation), and analytical methods for Carnosine determination, since one of the difficulties is the measurement of carnosines concentration in human samples.

Carnosine in health and disease

A review of the current literature relating to the potential therapeutic effects of carnosine in health and disease suggests that there is suggestive of a potential for carnosines to have therapeutic benefits inhealth and disease.

The Mitochondrial Disruptor Devimistat (CPI-613) Synergizes with Genotoxic Anticancer Drugs in Colorectal Cancer Therapy in a Bim-Dependent Manner

Investigation of the therapeutic potential of the compound devimistat (CPI-613) that targets altered mitochondrial cancer cell metabolism and its synergism with the antineoplastic drugs 5-fluorouracil (5-FU) and irinotecan (IT) in colorectal cancer revealed it as a promising candidate for coloreCTal cancer therapy by synergizing with established antineopolastic drugs in vitro and in vivo.

Non‐enzymatic reaction of carnosine and glyceraldehyde‐3‐phosphate accompanies metabolic changes of the pentose phosphate pathway

Carnosine's effect on metabolites and pathways in glioblastoma cells is analysed to determine its mode of action and its primary targets are unknown.

Blockade of glutamine-dependent cell survival augments antitumor efficacy of CPI-613 in head and neck cancer

CP-613, a novel lipoate analog, redirects cellular activity towards tumor-promoting glutaminolysis, leading to low anticancer efficacy in head and neck squamous cell carcinoma cells, and the addition of a GLS1 inhibitor CB-839 to CPI-613 treatment abrogates the metabolic dependency of HNSCC cells on glutamine, achieving a synergistic anticancer effect in glutamine-addicted H NSCC.

References

SHOWING 1-10 OF 42 REFERENCES

Carnosine Inhibits the Proliferation of Human Gastric Cancer SGC-7901 Cells through Both of the Mitochondrial Respiration and Glycolysis Pathways

The results suggested that carnosine is a potential regulator of energy metabolism of SGC-7901 cells both in the anaerobic and aerobic pathways, and provided a clue for preclinical and clinical evaluation of carnosines for gastric cancer therapy.

Carnosine Inhibits Growth of Cells Isolated from Human Glioblastoma Multiforme

Since carnosine is a naturally occurring substance that appears to be non-toxic to normal tissue and is able to penetrate the blood–brain barrier it may be a candidate for a therapeutic agent that may reduce proliferation of neoplastic cells even in vivo and especially in cases of glioblastoma multiforme.

Inhibition of the growth of transformed and neoplastic cells by the dipeptide carnosine.

Mixtures of normal MRC-5 fibroblasts and HeLa cells are used to demonstrate that 20 mM carnosine can selectively eliminate the tumour cells, and it is proposed that it depletes certain glycolysis intermediates.

The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth

It is demonstrated that M2 expression is necessary for aerobic glycolysis and that this metabolic phenotype provides a selective growth advantage for tumour cells in vivo.

Metabolic response of glioblastoma cells associated with glucose withdrawal and pyruvate substitution as revealed by GC-MS

A high plasticity of glioblastoma cells to changes in nutritional supply is revealed which has to be taken into account in clinical trials in which specific diets are considered for therapy.

Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo

We report the analysis of CPI-613, the first member of a large set of analogs of lipoic acid (lipoate) we have investigated as potential anticancer agents. CPI-613 strongly disrupts mitochondrial

Carnosine Inhibits the Proliferation of Human Gastric Carcinoma Cells by Retarding Akt/mTOR/p70S6K Signaling

The results showed that treatment with carnosine led to proliferation inhibition, cell cycle arrest in the G0/G1 phase, apoptosis increase, and inhibition of mTOR signaling activation by decreasing the phosphorylation of Akt, mTOR and p70S6K, suggesting that proliferation inhibition of Carnosine in human gastric carcinoma was through the inhibition ofAkt/mTOR/p70S 6K pathway, and Carnival would be a mimic of rapamycin.

Transient elevation of glycolysis confers radio-resistance by facilitating DNA repair in cells

These findings suggest that enhanced glycolysis generally observed in cancer cells may be responsible for the radio-resistance, partly by enhancing the repair of DNA damage.

[Increased manganese superoxide dismutase and cyclin B1 expression in carnosine-induced inhibition of glioblastoma cell proliferation].

It is shown that carnosine selectively inhibits proliferation of human glioblastoma cells (U-118-MG) compared to breast (MB231) and oral (Cal27 and FaDu) cancer cells, and it is concluded that the antiproliferative property of Carnival is due to its ability to enhance MnSOD and cyclin B1 expression.